The popularity of Sildenafil initially fueled a surge for major pharmaceutical companies, however recent developments present a uncertain picture for shareholders. Lower-cost versions are eating into earnings, and https://carajmyt025394.bloguerosa.com/39860260/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment